Effect of apolipoprotein C1 overexpression on drug resistance of liver cancer drug resistant cell HepG2/SR&nbsp;

doi:10.13418/j.issn.1001-165x.2026.2.08

PDF(3888 KB)

Chinese Journal of Clinical Anatomy ›› 2026, Vol. 44 ›› Issue (2) : 175-181. DOI: 10.13418/j.issn.1001-165x.2026.2.08

Effect of apolipoprotein C1 overexpression on drug resistance of liver cancer drug resistant cell HepG2/SR

Chen Liang¹, Hu Min¹, Zhao Song^2,3, Song Huijuan^2,3*

Author information +

History +

Abstract

Objective To investigate the effect of apolipoprotein C1 (APOC1) overexpression on drug resistance of liver cancer drug-resistant cells HepG2/SR and its possible mechanism. Methods The sorafenib resistant cells HepG2/SR were established by inducing the liver cancer HepG2 cells with a gradually increasing concentration of sorafenib. HepG2/SR cells were divided into a control and an APOC1 overexpression groups. CCK-8 assay and EdU labeling technique were used to detect cell proliferation activities and proliferation rates. Cell scratch assay was used to detect cell migration rates. Flow cytometry was used to detect cell apoptotic rates, and Western blotting to detect the expression levels of E-cadherin, N-cadherin and Vimentin proteins in the cells. Results Compared with the control cells, the proliferation activity, proliferation rate and migration rate of the HepG2/SR cells in APOC1 overexpression group were significantly decreased, the apoptotic rate of the cells was significantly increased, and the expression level of E-cadherin protein in the cells was significantly increased, while the expression levels of N-cadherin and Vimentin proteins were significantly decreased. Conclusions APOC1 overexpression can inhibit the proliferation, migration and promote the apoptosis of liver cancer drug resistant HepG2/SR cells. The mechanism may be related to the inhibition of protein expression involved in the epithelial-mesenchymal transition (EMT) process.

Key words

Apolipoprotein C1 / / / Liver cancer / / / Sorafenib resistance / / / Epithelial-mesenchymal transition

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Chen Liang, Hu Min, Zhao Song, Song Huijuan. Effect of apolipoprotein C1 overexpression on drug resistance of liver cancer drug resistant cell HepG2/SR [J]. Chinese Journal of Clinical Anatomy. 2026, 44(2): 175-181 https://doi.org/10.13418/j.issn.1001-165x.2026.2.08

References

[1] Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3[J]. Arterioscler Thromb Vasc Biol, 1999, 19(3): 472-484. DOI: 10.1161/01.atv.19.3.472.
[2] Yi J, Ren LW, Wu J, et al. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer[J]. Ann Transl Med, 2019, 7(16): 380. DOI:10.21037/atm. 2019. 07.59.
[3] 徐胜元, 毕林刚, 于志勇. 载脂蛋白C1在胃癌患者中的表达及其与预后的关系[J]. 重庆医学, 2020, 49(23): 3974-3978. DOI: 10.3969/j.issn.1671-8348.2020.23.026.
Xu SY, Bi LG, Yu ZY. Expression of apolipoprotein C1 in patients with gastric cancer and its relationship with prognosis[J]. Chongqing medicine, 2020, 49(23): 3974-3978. DOI:10.3969/j.issn.1671-8348. 2020.23.026.
[4] 杨凤鸣, 李聪, 冒学莲, 等. 肺癌患者血清载脂蛋白C1水平及临床意义[J]. 国际检验医学杂志, 2021, 42(23): 2839-2843. DOI:10.3969/j.issn.1673-4130.2021.23.005.
Yang FM, Li C, Mao XL, et al. Serum apolipoprotein C1 level in patients with lung cancer and its clinical significance[J]. Int J Lab Med, 2021, 42(23): 2839-2843. DOI: 10.3969/j.issn.1673-4130.2021.23.005.
[5] 张玉玺, 崔万里, 孙熙武, 等. 载脂蛋白C1在肾透明细胞癌中表达及意义[J]. 中国实验诊断学, 2023, 27(9): 1083-1087. DOI:10.3969/j.issn.1007-4287.2023.09. 021.
Zhang YX, Cui WL, Sun XW, et al. Expression and significance of apolipoprotein C1 in renal clear cell carcinoma[J]. Chin J Lab Diagn, 2023, 27(9): 1083-1087. DOI:10.3969/j.issn.1007-4287.2023.09. 021.
[6] Li RJ, He HX, He XX. APOC1 promotes the progression of osteosarcoma by binding to MTCH2[J]. Exp Ther Med, 2023, 25(4): 163. DOI:10.3892/etm.2023.11862.
[7] 宋慧娟, 徐振华, 何东宁. 载脂蛋白C1表达对人肝癌HepG2细胞增殖和凋亡的影响及其机制[J]. 吉林大学学报(医学版), 2024, 50(1): 128-135. DOI:10.13481/j.1671 -587X. 20240116.
Song HJ, Xu ZH, He DN. Effect of apolipoprotein C1 expression on proliferation and apoptosis of human liver cancer HepG2 cells and its mechanism[J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 128-135. DOI:10.13481/j.1671 -587X. 20240116.
[8] Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of Hepatocellular Carcinoma: A Review[J]. JAMA Surg, 2023, 158(4): 410-420. DOI: 10.1001/jamasurg.2022.7989.
[9] Chen W, Chiang CL, Dawson LA. Efficacy and safety of radiotherapy for primary livercancer[J]. Chin Clin Oncol, 2021,10(1): 9. DOI: 10.21037/cco-20-89.
[10]Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers[J]. Cancer Metastasis Rev, 2023, 42(3): 629-652. DOI:10.1007/s10555-023- 10084-4.
[11]Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline[J]. J Clin Oncol, 2020, 38(36): 4317-4345. DOI:10.1200/JCO. 20.02672.
[12]Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib[J]. Profiles Drug Subst Excip Relat Methodol, 2019, 44: 239-266. DOI: 10.1016/bs.podrm.2018.11.003.
[13]Zhang C, Jiang WQ, Ding J. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy[J]. Biochim Biophys Acta Rev Cancer, 2020,1874(1):188382. DOI:10.1016/j.bbcan. 2020.188382.
[14]Ren H, Chen ZH, Yang L. Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer[J]. Cancer Manag Res, 2019,11:4917-4930.DOI:10.2147/CMAR.S192529.
[15]Cao XY, Wu BQ, Guo SM, et al. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis[J]. Pathol Oncol Res, 2023, 29: 1610976. DOI:10.3389/pore.2023.1610976.
[16]Yan Y, Zhou YH, Wang K. Apolipoprotein C1 (APOC1), A Candidate Diagnostic Serum Biomarker for Breast Cancer Identified by Serum Proteomics Study[J]. Crit Rev Eukaryot Gene Expr, 2022, 32(4): 1-9. DOI:10.1615/CritRevEukaryotGeneExpr. 2021040967.
[17]Fedele M, Sgarra R, Battista S, et al. The epithelial–mesenchymal transition at the crossroads between metabolism and tumor progression[J]. Int J Mol Sci, 2022, 23(2): 800. DOI:10.3390 /ijms23020800.
[18]Debnath P, Huirem RS, Dutta P, et al. Epithelial-mesenchymal transition and its transcription factors[J]. Biosci Rep, 2022, 42(1): BSR20211754. DOI:10.1042/ BSR20211754.
[19]Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition [J]. Nat Rev Mol Cell Biol, 2014, 15(3): 178-196. DOI:10.1038/ nrm3758.
[20]高佳丰. EGF/EGFR/EMT通路介导肝癌索拉非尼耐药及其机制研究[D]. 淮南: 安徽理工大学, 2024. DOI: 10.26918/d.cnki.ghngc.2024. 000589.
Gao JF. Research on the resistance and mechanisms of EGF/EGFR/EMT pathway mediated sorafenib resistance in hepatocellular carcinoma[D]. Huainan: Anhui University of Science and Technology, 2024. DOI:10.26918/d.cnki.ghngc.2024.000589.
[21]张彦吉, 隋红, 王凯冰. EMT在肝细胞肝癌耐药中的分子机制研究进展[J]. 现代肿瘤医学, 2024, 32 (1): 172-177. DOI: 10.3969/j.issn.1672-4992.2024.01.033.
Zhang YJ, Sui H, Wang KB. Research progress on molecular mechanism of EMT in drug resistance of hepatocellular carcinoma[J]. Modern Oncology, 2024, 32 (1): 172-177. DOI:10.3969/j.issn.1672-4992.2024. 01.033.
[22]Malenstein HV, Dekervel J, Verslype C, et al. Long-term exposure to sorafenib of liver cancercells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth[J]. Cancer Lett, 2013, 329(1):74-83.DOI:10.1016/j.canlet.2012. 10.021.
[23]Huang XY, Ke AW, Shi GW, et al. alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma[J]. Hepatology, 2013, 57(6): 2235-2247. DOI: 10.1002/ hep.26255.
[24]Xia P, Zhang H, Xu KQ, et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma[J]. Cell Death Dis, 2021, 12(7): 691. DOI: 10.1038/ s41419-021-03973-5.
[25]Zhang PF, Wang F, Wu J, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234(3): 2788-2794. DOI: 10.1002/jcp.27095.